SYS-CON MEDIA Authors: David H Deans, Kevin Benedict, Gilad Parann-Nissany, Michael Bushong, Eric Brown

News Feed Item

Momentum Indicators for Health Care Equities -- Research on Arena Pharma, Hemispherx Biopharma, PDL BioPharma and Celgene

Editor Note: For more information about this release, please scroll to bottom

LONDON, March 20, 2014 /PRNewswire/ --

The trading session on Wednesday, March 19, 2014 ended on a negative note as the S&P 500 finished at 1,860.77, down 0.61%; the NASDAQ Composite closed at 4,307.60, down 0.59%; the Dow Jones Industrial Average finished the session 0.70% lower at 16,222.17. The losses were broad based as all the sectors ended the session in negative. The S&P 500 Health Care Sector Index finished the day at 686.44, down 0.37%, while the same has advanced 1.72% in the previous three trading sessions. Investor-Edge has initiated coverage on the following equities: Arena Pharmaceuticals Inc. (NASDAQ: ARNA), Hemispherx Biopharma Inc. (AMEX: HEB), PDL BioPharma Inc. (NASDAQ: PDLI) and Celgene Corp. (NASDAQ: CELG). Free technical research on ARNA, HEB, PDLI and CELG can be downloaded upon signing up at:

http://www.investor-edge.com/365-register

Shares in Arena Pharmaceuticals Inc. recorded a trading volume of 3.34 million shares, as compared with a three months average volume of 5.81 million shares. The stock ended the day at $6.52, down 1.29% and at an intraday range of $6.46 and $6.67. Arena Pharmaceuticals Inc. shares have declined 2.91% in the last one month, while the same has gained 0.39% in the previous three trading sessions and 11.37% on YTD basis. The company's stock is trading above its 200-day moving average. Arena Pharmaceuticals Inc.'s 50-day moving average of $6.74 is above the 200-day moving average of $6.39. Furthermore, the stock is trading at the Relative Strength Index (RSI) of 46.11. Sign up today to read free research on ARNA at:

http://www.investor-edge.com/365-ARNA-20Mar2014.pdf

On Wednesday, shares in Hemispherx Biopharma Inc. edged 0.38% lower to finish the day at $0.40. The stock recorded a trading volume of 1.07 million shares as compared to a three months average volume of 3.14 million shares. The stock fluctuated between $0.39 and $0.41 during the session. Hemispherx Biopharma Inc.'s stocks have advanced 1.20% in the previous three trading sessions, 1.90% in the last one month, and 49.92% on YTD basis. The company's shares are trading above its 200-day moving average. Hemispherx Biopharma Inc.'s 50-day moving average of $0.40 is above the 200-day moving average of $0.28. Moreover, the stock is trading at the Relative Strength Index (RSI) of 49.48. Sign up today to read free research on HEB at:

http://www.investor-edge.com/365-HEB-20Mar2014.pdf

PDL BioPharma Inc.'s stock finished Wednesday's session at its previous day's closing price of $8.61. A total of 4.38 million shares were traded, which is above the three months average volume of 2.74 million. The company's shares oscillated between $8.46 and $8.70 during the trading session. Shares of the company traded at a PE ratio of 4.98. PDL BioPharma Inc.'s shares have gained 4.24% in the previous three trading sessions, 0.94% in the last one month, and 2.01% on YTD basis. The company's stock is trading above its 200-day moving average. PDL BioPharma Inc.'s 50-day moving average of $8.62 is above the 200-day moving average of $8.29. Furthermore, the stock is trading at the Relative Strength Index (RSI) of 53.46. Sign up today to read free research on PDLI at:

http://www.investor-edge.com/365-PDLI-20Mar2014.pdf

Shares in Celgene Corp. recorded a trading volume of 2.85 million shares, as compared with a three months average volume of 3.22 million shares. The stock finished the day at $150.84, down 1.85% after trading between $150.11 and $155.99. Shares of the company traded at a PE ratio of 32.23. Celgene Corp.'s stocks have advanced 0.96% in the previous three trading sessions, while the same has declined 7.46% in the last one month and 10.73% on YTD basis. The company's stock is trading above its 200-day moving average. Celgene Corp.'s 50-day moving average of $160.49 is above the 200-day moving average of $149.04. Additionally, shares of the company are trading at the Relative Strength Index (RSI) of 42.27. Sign up today to read free research on CELG at:

http://www.investor-edge.com/365-CELG-20Mar2014.pdf


===============
EDITOR'S NOTES:
===============

1. This is not company news. We are an independent source and our views do not reflect the companies mentioned.

2. Information in this release is fact checked and produced on a best efforts basis and reviewed by Nidhi Vatsal, a CFA charterholder. However, we are only human and are prone to make mistakes. If you notice any errors or omissions, please notify us below.

3. This information is submitted as a net-positive to companies mentioned, to increase awareness for mentioned companies to our subscriber base and the investing public.

4. If you wish to have your company covered in more detail by our team, or wish to learn more about our services, please contact us at pubco [at] http://www.investor-edge.com.

5. For any urgent concerns or inquiries, please contact us at compliance [at] http://www.investor-edge.com.

6. Are you a public company? Would you like to see similar coverage on your company? Send us a full investors' package to research [at] http://www.investor-edge.com for consideration.

COMPLIANCE PROCEDURE
Content is researched, written and reviewed on a best-effort basis. This document, article or report is prepared and authored by Investor-edge. An outsourced research services provider represented by Nidhi Vatsal, CFA, has only reviewed the information provided by Investor-edge in this article or report according to the Procedures outlined by Investor-edge. Investor-edge is not entitled to veto or interfere in the application of such procedures by the outsourced provider to the articles, documents or reports, as the case may be.

NOT FINANCIAL ADVICE
Investor-edge makes no warranty, expressed or implied, as to the accuracy or completeness or fitness for a purpose (investment or otherwise), of the information provided in this document. This information is not to be construed as personal financial advice. Readers are encouraged to consult their personal financial advisor before making any decisions to buy, sell or hold any securities mentioned herein.

NO WARRANTY OR LIABILITY ASSUMED
Investor-edge is not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted by Investor-edge whatsoever for any direct, indirect or consequential loss arising from the use of this document. Investor-edge expressly disclaims any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Investor-edge does not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice.

CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.

SOURCE Investor-Edge

More Stories By PR Newswire

Copyright © 2007 PR Newswire. All rights reserved. Republication or redistribution of PRNewswire content is expressly prohibited without the prior written consent of PRNewswire. PRNewswire shall not be liable for any errors or delays in the content, or for any actions taken in reliance thereon.